Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658384 | 0.88 | ATM (0.55) | ATMKMT2ADRD2DRD4SIGMAR1 | |
| SCHEMBL19658394 | 0.86 | ATM (0.53) | ATMKMT2ADRD2DRD4SIGMAR1 | |
| SCHEMBL19658607 | 0.86 | CXCR4 (0.56) | ATMDRD2DRD4ALDH1A1POLB | |
| SCHEMBL19652159 | 0.84 | ACHE (0.60) | ACHE | |
| SCHEMBL26384526 | 0.83 | DRD2 (0.50) | ATMKMT2ADRD2DRD4SIGMAR1 | |
| SCHEMBL17754011 | 0.82 | ATM (0.63) | ATMKMT2ADRD2DRD4SIGMAR1 | |
| SCHEMBL19652286 | 0.82 | SLC6A4 (0.49) | ACHE | |
| SCHEMBL19652183 | 0.81 | CYP2D6 (0.53) | DRD2DRD4SIGMAR1ALDH1A1ACHE | |
| SCHEMBL19652186 | 0.77 | CXCR4 (0.50) | KMT2ADRD2DRD4MEN1ALDH1A1 | |
| SCHEMBL24495004 | 0.77 | ATM (0.63) | ATMKMT2ADRD2DRD4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | ATM 1939/4885KMT2A 165/4885DRD2 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.